Results 21 to 30 of about 24,614 (195)

Comparison of Intravitreal Bevacizumab Upload Followed by a Dexamethasone Implant versus Dexamethasone Implant Monotherapy for Retinal Vein Occlusion with Macular Edema [PDF]

, 2012
Purpose: To compare the efficacy and safety of three intravitreal bevacizumab upload injections followed by a dexamethasone implant versus dexamethasone implant monotherapy in eyes with macular edema due to retinal vein occlusion.
Haritoglou, Christos, Kampik, Anselm, Kook, Daniel, Mayer, Wolfgang J., Remy, Matthias, Reznicek, Lukas, Ulbig, Michael, Wolf, Armin   +7 more
core   +1 more source

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema

Journal of Ophthalmology, 2018
Purpose. To compare the visual and anatomic outcomes in patients with persistent diabetic macular edema (DME) who switched from ranibizumab to aflibercept with those who continued with previous ranibizumab therapy. Methods.
Ali Demircan, Zeynep Alkin, Ceren Yesilkaya, Gokhan Demir, Burcu Kemer   +4 more
doaj   +1 more source

Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article [PDF]

, 2017
Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for neovascular age-related macular degeneration (nAMD).
Elena Gusson, Giacomo Panozzo, Giorgio Boschi, Giuseppe Scarpa, Nicola Zemella, null null, Sandro Saviano, Stefania Miotto, Stefano Piermarocchi   +8 more
core   +1 more source

Early CRT monitoring using time-domain optical coherence tomography does not add to visual acuity for predicting visual loss in patients with central retinal vein occlusion treated with intravitreal ranibizumab:A secondary analysis of trial data [PDF]

, 2017
Our primary purpose was to assess the clinical (predictive) validity of central retinal thickness (CRT) and best corrected visual acuity (BCVA) at 1 week and 1 month after starting treatment with ranibizumab for central retinal vein occlusion.
Bell, Katy J L, Duerr, Hans Peter, Farris, Maria, Glasziou, Paul, Hayen, Andrew, Irwig, Les, Mitchell, Andrew S., Mitchell, Paul, Wright, Jonathan   +8 more
core   +2 more sources

Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon’s Fibroblasts

Biomolecules, 2019
The anti-fibrotic properties of ranibizumab have been well documented. As an antagonist to vascular endothelial growth factor (VEGF), ranibizumab works by binding and neutralizing all active VEGF-A, thus limiting progressive cell growth and proliferation.
Siti Munirah Md Noh, Siti Hamimah Sheikh Abdul Kadir, Sushil Vasudevan   +2 more
doaj   +1 more source

Comparison between “early” or “late” intravitreal injection of dexamethasone implant in branch (BRVO) or central (CRVO) retinal vein occlusion: six months follow-up [PDF]

, 2017
AIM: The aim of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-months follow-up.
AUTOLITANO, MONICA, BASILI, Stefania, LA TORRE, Giuseppe, LENZI, TOMMASO, PACELLA, Elena, PACELLA, FERNANDA, Pascarella, Antonella   +6 more
core   +1 more source

The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients

Scientific Reports, 2021
The ZIPANGU study assessed the efficacy and safety of ranibizumab as a one loading dose + pro re nata (one + PRN) regimen with/without focal/grid laser among treatment-naïve patients suffering from macular edema (ME) following branch retinal vein ...
Toshinori Murata, Mineo Kondo, Makoto Inoue, Shintaro Nakao, Rie Osaka, Chieko Shiragami, Kenji Sogawa, Akikazu Mochizuki, Rumiko Shiraga, Yohei Ohashi, Takeumi Kaneko, Chikatapu Chandrasekhar, Akitaka Tsujikawa, Motohiro Kamei   +13 more
doaj   +1 more source

Adverse events associated with intraocular injection of anti-VEGF(bevacizumab) in retinal vein ccclusion: a case report [PDF]

, 2015
Introduction: Antiangiogenic agents are often administered for treatment of Branch Retinal Vein Occlusion (BRVO). Among them, Bevacizumab has noticeable antiangiogenic and antiedemigenic properties and possesses great capacity to penetrate the retinal ...
ARTICO, Marco, BOTTONE, Andrea, Domenica Piraino, Carmen, Mollicone, Antonella, PACELLA, Elena, PACELLA, FERNANDA, Romana Parisiella, Francesca, TURCHETTI, PAOLO   +7 more
core   +1 more source

Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study.

PLoS ONE, 2020
PURPOSE:To assess the 1-year effectiveness, safety, and treatment patterns of ranibizumab in patients with myopic choroidal neovascularization (mCNV) enrolled in the LUMINOUS study.
Robin D Hamilton, Andreas Clemens, Angelo Maria Minnella, Timothy Y Y Lai, Hong Dai, Taiji Sakamoto, Chui Ming Gemmy Cheung, Nor Fariza Ngah, Cornelia Dunger-Baldauf, Frank G Holz, LUMINOUS study group   +10 more
doaj   +1 more source

Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. [PDF]

, 2020
AimTo show the characteristics and outcomes of patients with neovascular age-related macular degeneration (nAMD) who had extended remission (ER) while on a pro re nata (PRN) treatment protocol.MethodsThis was a retrospective case-control study of a ...
Amador-Patarroyo, Manuel J, Cheng, Lingyun, Dans, Kunny C, Freeman, William R, Lin, Tiezhu, Meshi, Amit, Muftuoglu, Ilkay Kilic   +6 more
core